<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Sat, 03 Jan 2026 07:00:13 +0000</lastBuildDate>
    <item>
      <title>#1 [85/100] Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41482527/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41482527/</guid>
      <dc:creator>Riaz N, Alban TJ, Haddad RI, Saul M, Makarov V, Zhu Y, Cohen EEW, Ferris RL, Chang PM, Lin JC, et al.</dc:creator>
      <pubDate>Fri, 02 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚≠ê HIGH IMPACT - Score: 85/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study is a phase 3 international randomized trial examining the efficacy of avelumab combined with chemoradiotherapy in head and neck cancer, providing important insights into tumor characteristics that influence treatment outcomes, which could lead to practice-changing implications.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Riaz N, Alban TJ, Haddad RI, Saul M, Makarov V, Zhu Y, Cohen EEW, Ferris RL, Chang PM, Lin JC, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s43018-025-01068-0'&gt;10.1038/s43018-025-01068-0&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-02&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41482527/'&gt;41482527&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Immune checkpoint blockade-based multimodal therapy is widely used across oncology; yet drivers of resistance in most cancer types are not well understood. Here, we comprehensively characterized the tumor genome, microenvironment and microbiome in a phase 3 international randomized trial ( NCT02952586 ) to identify factors that shape outcomes to anti-PD-L1 avelumab plus standard-of-care chemoradiotherapy versus placebo/chemoradiotherapy in individuals with locally advanced head and neck cancer. Patients receiving avelumab whose tumors contained distinct immunologic and genetic features had superior outcomes compared to those receiving placebo. By contrast, patients with increased myeloid/neutrophil activities had worse outcomes with avelumab than those treated with placebo. Strikingly, these tumors possessed telltale intratumoral bacteria, elevated tumor-associated neutrophils, high systemic neutrophil-to-lymphocyte ratios and suppressed adaptive immunity. We define tumor ecosystems associated with benefit to chemoimmunotherapy. Our data demonstrate how intratumoral bacteria affect immune checkpoint blockade response within a randomized trial. These discoveries enhance our understanding of combination immunotherapy, provide a useful multiomic resource and identify unanticipated interactions that may guide future therapeutic strategies.</description>
    </item>
    <item>
      <title>#2 [75/100] Tumor bacterial burden dictates immunotherapy fate in head and neck cancer.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41482525/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41482525/</guid>
      <dc:creator>Jhawar SR, Spakowicz D</dc:creator>
      <pubDate>Fri, 02 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The study explores the relationship between tumor bacterial burden and immunotherapy outcomes, which could provide important insights into treatment responses, but lacks the robustness of a large prospective study or RCT.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Jhawar SR, Spakowicz D&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s43018-025-01074-2'&gt;10.1038/s43018-025-01074-2&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-02&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41482525/'&gt;41482525&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#3 [75/100] Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41482523/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41482523/</guid>
      <dc:creator>Silver NL, Dai J, Kerr TD, Altemus J, Garg R, Simmons H, Alban T, Noel-Romas L, Makarov V, Shih DJH, et al.</dc:creator>
      <pubDate>Fri, 02 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents important findings on the role of intratumoral bacteria in predicting immunotherapy response in HNSCC, utilizing data from a clinical trial and validating results across multiple cohorts, which could influence future treatment strategies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Silver NL, Dai J, Kerr TD, Altemus J, Garg R, Simmons H, Alban T, Noel-Romas L, Makarov V, Shih DJH, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s43018-025-01067-1'&gt;10.1038/s43018-025-01067-1&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-02&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41482523/'&gt;41482523&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Despite the promise of immune checkpoint blockade (ICB) in head and neck squamous cell carcinoma (HNSCC), mediators of response are poorly understood. To address this, here we analyzed oropharyngeal HNSCCs treated with neoadjuvant durvalumab (anti-PDL1) alone or in combination with tremelimumab (anti-CTLA4) from the CIAO clinical trial ( NCT03144778 ). We found that only the total abundance of intratumoral bacteria predicted ICB response, which was validated in multiple independent cohorts. High intratumoral bacteria abundance was associated with an immunosuppressive tumor microenvironment, characterized by an accumulation of neutrophils coupled with depletion of T cells and other adaptive immune cells. Experimental elevation or reduction in intratumoral bacteria abundance in orthotopic models of HNSCC in female mice recapitulated immunological associations observed in participant tumors. Increasing intratumoral bacteria abundance was sufficient to induce resistance to anti-PDL1 ICB, irrespective of bacterial species tested. Together, these findings demonstrate that high intratumoral bacteria abundance is a key suppressor of antitumor immunity and promotes immunotherapy resistance.</description>
    </item>
    <item>
      <title>#4 [75/100] Prevalence, incidence, and dynamics of oral human papillomavirus infection among healthy individuals-A molecular epidemiology field study from India.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41467594/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41467594/</guid>
      <dc:creator>Vani NV, Madhanagopal R, Subramanian MJ, Sundersingh S, Helen AX, Meenakumari B, Rao DM, Ganesan TS, Swaminathan R</dc:creator>
      <pubDate>Tue, 30 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study is a large prospective cohort analysis with over 5000 participants investigating the prevalence of oral HPV, which has significant implications for understanding head and neck cancer risk, although it does not directly address treatment or clinical outcomes.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Vani NV, Madhanagopal R, Subramanian MJ, Sundersingh S, Helen AX, Meenakumari B, Rao DM, Ganesan TS, Swaminathan R&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; International journal of cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ijc.70298'&gt;10.1002/ijc.70298&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-30&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41467594/'&gt;41467594&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Persistent infection with human papillomavirus (HPV) is associated with an increased risk of head and neck cancers (HNC), particularly oropharyngeal cancer. This longitudinal cohort study investigated the prevalence and dynamics of oral HPV infection among healthy adults in South India. A total of 5325 participants were enrolled, and demographic, behavioral, and oral gargle samples were collected. HPV deoxyribonucleic acid (DNA) was detected using nested PCR (PGMY/GP) and genotyped by Sanger sequencing. HPV16 messenger ribonucleic acid (mRNA) expression was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR) and validated using droplet digital polymerase chain reaction (ddPCR). Logistic regression analyses were performed to estimate odds ratios. At baseline, 5011 samples were analyzed; 274 (5.5%) were HPV-positive and 4737 were negative. Among 3792 initially HPV-negative participants followed up, 126 (3.3%) acquired new infections (median 8‚Äâmonths; range, 6-15‚Äâmonths). Of 274 baseline HPV-positive individuals, 241 were followed up: 24 (10%) showed persistence, while 217 (90%) cleared infection after a median of 9‚Äâmonths (range, 6-20‚Äâmonths). Sanger sequencing of 471 samples from prevalent and incident infections yielded 290 (61.6%) high-quality sequences; 284 (98%) were HPV16, with isolated detections of HPV18, HPV66, HPV70, and HPV89. Ten novel variants were identified-nine HPV16 and one HPV89-while remaining sequences aligned with established Indian cervical HPV lineages. None of the 176 HPV16 DNA-positive samples analyzed expressed mRNA by RT-PCR, confirmed in 136 samples using ddPCR. Oral HPV infection among healthy individuals in India appears predominantly transient. Long-term monitoring may elucidate the oncogenic potential of oral HPV in this population.</description>
    </item>
    <item>
      <title>#5 [75/100] Accuracy and Clinical Significance of Intraoperative Gross Extrathyroidal Extension (T3b) Assessment in Differentiated Thyroid Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41463164/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41463164/</guid>
      <dc:creator>An S, Park J, Kim K, Bae JS</dc:creator>
      <pubDate>Sun, 07 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study involves a large cohort of nearly 5000 patients and addresses an important clinical question regarding the accuracy of intraoperative assessment of extrathyroidal extension in differentiated thyroid carcinoma, which could have implications for staging and treatment outcomes.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; An S, Park J, Kim K, Bae JS&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Cancers | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.3390/cancers17243914'&gt;10.3390/cancers17243914&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-07&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41463164/'&gt;41463164&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: In the eighth edition of the American Joint Committee on Cancer tumor-node-metastasis staging system, gross extrathyroidal extension (ETE) into the strap muscles is classified as T3b when identified during surgery. In clinical practice, this invasion is primarily assessed intraoperatively by the surgeon and documented in the operative report, forming the basis of the final T3b staging. Because this evaluation is inherently subjective, its diagnostic accuracy remains uncertain. This study evaluated the accuracy of intraoperative gross ETE assessment and whether misclassification affects recurrence outcomes. METHODS: In total, 4987 patients who underwent thyroidectomy at Seoul St. Mary's Hospital during 2017-2022 were analyzed. Patients were categorized by concordance between intraoperative findings and final pathology: confirmed gross ETE (Group A), intraoperative overestimation (Group B), and intraoperative underestimation (Group C). Clinical characteristics, recurrence rates, and predictors of inaccurate assessment were compared. RESULTS: Of the cohort, 179 patients (3.6%) were judged intraoperatively to have gross ETE, classified as Group A (141 patients), Group B (38), and Group C (33). Recurrence rates were not significantly different among groups (6.4%, 2.6%, and 3.0% in Groups A, B, and C, respectively). Other than lymphatic invasion and tumor size, baseline characteristics were comparable among groups. Multivariate analysis identified age (odds ratio [OR]: 0.961; 95% confidence interval [CI]: 0.932-0.990; p = 0.009), tumor location (OR: 0.182; 95% CI: 0.056-0.591; p = 0.005), and lymphatic invasion (OR: 0.292; 95% CI: 0.118-0.719; p = 0.007) as independent predictors of inaccurate intraoperative evaluation. CONCLUSIONS: Among 179 patients suspected of gross ETE intraoperatively, 21.2% showed no muscle invasion on pathology. Although recurrence rates were similar across groups, recurrence-free survival tended to be lower in Group A relative to Group B, indicating the potential prognostic relevance of accurate intraoperative T3b identification. Long-term follow-up is needed to confirm this trend.</description>
    </item>
    <item>
      <title>#6 [70/100] Positron emission tomography-based intratumoral spatial diversity for prognosis in nasopharyngeal carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41481965/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41481965/</guid>
      <dc:creator>Niu S, Ding J, Chen H, Zhu Z, Liao X, Hong H, Chen C, Dong J, Fei Z</dc:creator>
      <pubDate>Thu, 01 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter retrospective study with a substantial sample size of 760 patients provides important insights into intratumoral heterogeneity in nasopharyngeal carcinoma, potentially enhancing risk stratification, though it lacks the definitive evidence or practice-changing findings characteristic of higher-impact studies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Niu S, Ding J, Chen H, Zhu Z, Liao X, Hong H, Chen C, Dong J, Fei Z&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2025.107845'&gt;10.1016/j.oraloncology.2025.107845&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-01&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41481965/'&gt;41481965&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: This study aimed to develop a radiomics-based framework for quantifying intratumoral heterogeneity (ITH) in nasopharyngeal carcinoma (NPC) using three-dimensional tumor subregions. The goal was to enhance conventional clinical risk stratification and investigate the biological basis of ITH. METHODS: This multicenter retrospective study included PET scans from 760 treatment-na√Øve NPC patients. Radiomics features were extracted from the whole tumor (WT), and the intratumoral spatial diversity score (ITSDS) was simultaneously quantified through subregion analysis. After a multi-step feature selection process, both WT and ITH models were developed. Finally, a nomogram was constructed by integrating ITSDS with clinical factors. All models were evaluated using the C-index, AUC, and calibration curves, and their performance was interpreted using SHAP. Additionally, the biological characteristics of the ITH model were analyzed using tissue proteomics. RESULTS: The training, internal validation, and external validation cohorts included 480, 235, and 45 patients, respectively. The ITH model showed superior C-indexes of 0.852, 0.792, and 0.757 compared to the clinical and WT models. The nomogram demonstrated the best prognostic value, with C-indexes of 0.864, 0.817, and 0.772 in the three cohorts, respectively. The nomogram effectively classified patients into risk groups for progression-free survival (P¬†&lt;¬†0.01). Tissue proteomic analysis revealed upregulated ciliary movement, a more complex tumor microenvironment, and impaired immune function in the high-ITH group. CONCLUSION: The nomogram integrating ITSDS biomarkers with clinical factors improved risk stratification accuracy and created a clinically translatable framework for NPC. This approach potentially offers mechanistic insights into ITH and holds promise for advancing precision oncology.</description>
    </item>
    <item>
      <title>#7 [70/100] Development and validation of a risk nomogram for predicting central lymph node metastasis in papillary thyroid microcarcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41478265/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41478265/</guid>
      <dc:creator>Zhang W, Wu X, Wang Y, Le Q, Xie Y, Yu K</dc:creator>
      <pubDate>Wed, 31 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a large, multi-center validation of a risk nomogram for predicting central lymph node metastasis in papillary thyroid microcarcinoma, which has important clinical implications for management, although it is not a randomized controlled trial or a phase study.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Zhang W, Wu X, Wang Y, Le Q, Xie Y, Yu K&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2025.107842'&gt;10.1016/j.oraloncology.2025.107842&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-31&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41478265/'&gt;41478265&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: The global incidence of papillary thyroid microcarcinoma (PTMC) continues to rise, and the optimal management strategy remains controversial due to its generally favorable prognosis. Central lymph node metastasis (CLNM) is an important predictor of recurrence and survival and therefore plays a critical role in guiding therapeutic decision-making. This study aimed to develop and validate a nomogram to preoperatively predict the risk of CLNM in PTMC patients. METHODS: Patients from ward A (n¬†=¬†877) were assigned to the training cohort, and those from ward B (n¬†=¬†637) formed the validation cohort. Clinical characteristics and ultrasonographic variables were evaluated. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of CLNM, which were subsequently incorporated into a predictive nomogram. Model performance was assessed using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA). RESULTS: Univariate analysis identified gender, age, maximum tumor diameter (MTD), multifocality, calcification and capsule status as significantly associated with CLNM (P¬†&lt;¬†0.05). Multivariate logistic regression analysis revealed gender, age, MTD, multifocality, and capsule status as independent predictors. The nomogram demonstrated good discriminative ability, with an area under the curve (AUC) of 0.724 in the training cohort and 0.708 in the validation cohort. Calibration curves showed excellent agreement between predicted and observed outcomes, and DCA confirmed favorable clinical utility. CONCLUSION: We successfully developed and validated a clinically applicable nomogram that integrates preoperative clinical and ultrasonographic features to predict CLNM in PTMC patients. This model may assist clinicians in tailoring surgical strategies and optimizing individualized management.</description>
    </item>
    <item>
      <title>#8 [70/100] Exercise and quality of life in head and neck squamous cell carcinoma patients receiving neoadjuvant immuno-chemotherapy: A randomized, open-labeled phase II trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41478264/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41478264/</guid>
      <dc:creator>Xiao G, Ning L, Chen L, Zhang S, Chen Y, Chen Y</dc:creator>
      <pubDate>Wed, 31 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a randomized phase II trial with a focus on quality of life in HNSCC patients undergoing neoadjuvant immuno-chemotherapy, which is an important clinical question; however, the sample size is moderate and the findings may not be practice-changing.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Xiao G, Ning L, Chen L, Zhang S, Chen Y, Chen Y&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2025.107844'&gt;10.1016/j.oraloncology.2025.107844&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-31&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41478264/'&gt;41478264&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) significantly impairs patients' quality of life (QoL). While neoadjuvant immuno-chemotherapy offers potential survival benefits, it is associated with substantial treatment-related toxicities, including fatigue, sleep disturbances, and functional decline. Exercise therapy has shown promise in improving QoL in other cancers, but its role in HNSCC patients receiving neoadjuvant therapy remains underexplored. METHODS: This single-center, open-label, randomized phase II trial enrolled 114 HNSCC patients undergoing neoadjuvant immuno-chemotherapy. Participants were randomized 1:1 to an exercise group (personalized breathing and aerobic exercise program) or a control group (routine care). Outcomes were assessed using the BFI-C, EORTC QLQ-C30, QLQ-H&amp;N35, and PSQI at baseline, after 2 cycles, and after 3 cycles of therapy. RESULTS: The exercise group demonstrated significantly lower fatigue scores (BFI) after 2 and 3 cycles compared to controls (P &lt; 0.05). Sleep quality (PSQI) improved significantly in the exercise group and worsened in the control group. The exercise group also showed better outcomes in physical functioning, fatigue and insomnia. CONCLUSION: Exercise therapy is feasible and effective in reducing fatigue and improving sleep quality in HNSCC patients receiving neoadjuvant immuno-chemotherapy. Early integration of exercise may mitigate treatment-related symptoms and improve tolerance and overall QoL.</description>
    </item>
    <item>
      <title>#9 [70/100] Thyroglobulin Cutoffs after Total Thyroidectomy Without Radioiodine in Low- to Intermediate-Risk Thyroid Cancer: A Multicenter Cohort Study.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41467912/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41467912/</guid>
      <dc:creator>Kim M, Lee EK, Kim KJ, Shin SM, Jang J, Shin JY, Jin M, Bae JS, Kim K, Kim WG, et al.</dc:creator>
      <pubDate>Tue, 23 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter cohort study involves a large sample size (n=9753) and addresses an important clinical question regarding thyroglobulin cutoffs in thyroid cancer, which has implications for risk stratification, although it is a retrospective analysis and not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Kim M, Lee EK, Kim KJ, Shin SM, Jang J, Shin JY, Jin M, Bae JS, Kim K, Kim WG, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Thyroid : official journal of the American Thyroid Association | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1177/10507256251409134'&gt;10.1177/10507256251409134&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-23&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41467912/'&gt;41467912&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Background: The prognostic value of unstimulated serum thyroglobulin (Tg) levels for structural recurrence in patients with low- to intermediate-risk differentiated thyroid cancer (DTC) who underwent total thyroidectomy but did not receive radioactive iodine (RAI) therapy remains unclear. This study aimed to determine Tg cutoff values and evaluate the role of dynamic Tg monitoring in risk stratification in these patients. Methods: We retrospectively analyzed 9753 patients with low- to intermediate-risk DTC who underwent total thyroidectomy without RAI at 11 Korean tertiary hospitals. Serum Tg levels were measured under thyrotropin suppression (&lt;2 mIU/L) at 6, 12, and 24 months postoperatively using high-sensitive assays (functional sensitivity, &lt;0.2 ng/mL). Optimal Tg cutoffs were determined by receiver operating characteristic curves and survival analyses. Results: Higher postoperative unstimulated Tg levels consistently predicted structural recurrence, with an optimal cutoff of 0.3 ng/mL (area under the curve: 0.815, 0.772, and 0.816 at 6, 12, and 24 months, respectively). A Tg ‚â• 0.2 ng/mL, the Korean Thyroid Association (KTA) guideline cutoff for biochemical remission (excellent response), showed high sensitivity for recurrence. Tg ‚â• 5.0 ng/mL at 6 months, a KTA-defined threshold for a biochemical incomplete response, independently predicted an elevated recurrence risk. Kaplan-Meier curves showed stepwise declines in recurrence-free survival with increasing Tg levels. Notably, even Tg &lt; 0.2 or &lt; 0.3 ng/mL were associated with recurrence if levels rose over time. Conclusion: Unstimulated Tg levels are strongly associated with the risk of structural recurrence in patients with DTC who have undergone total thyroidectomy without RAI. The current cutoff values of 0.2 ng/mL and 5.0 ng/mL were clinically relevant, and Tg kinetics over time further improved risk stratification. These findings provide the first large-scale evidence from an East Asian cohort and underscore the importance of early, serial Tg assessment in this growing patient population.</description>
    </item>
    <item>
      <title>#10 [65/100] Clinical Trial Termination or Withdrawal in Head and Neck Squamous Cell Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41481330/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41481330/</guid>
      <dc:creator>Huang JJ, Reznik AS, Sonis S, Franzmann EJ, Villa A</dc:creator>
      <pubDate>Fri, 02 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study analyzes the characteristics associated with clinical trial failures in HNSCC, providing important insights into trial design and execution, but it is based on retrospective data and does not present novel therapeutic findings or practice-changing results.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Huang JJ, Reznik AS, Sonis S, Franzmann EJ, Villa A&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; JAMA otolaryngology-- head &amp; neck surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1001/jamaoto.2025.4766'&gt;10.1001/jamaoto.2025.4766&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-02&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41481330/'&gt;41481330&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;IMPORTANCE: Innovative clinical trials (CTs) are needed to address the rising incidence of head and neck squamous cell carcinoma (HNSCC). Despite adequate trial initiation, HNSCC CTs experience high failure rates, and the factors driving these trends remain unclear. OBJECTIVE: To assess the characteristics associated with failure (termination or withdrawal) in CTs for the treatment of HNSCC. DESIGN AND SETTING: HNSCC CTs were identified on ClinicalTrials.gov from January 1, 2000, to December 31, 2024, and trial failures were defined as early termination or withdrawal. Trial characteristics were compared between failed CTs and completed CT controls. Data were analyzed from June to August 2025. MAIN OUTCOMES AND MEASURES: The primary outcome was trial failure. The association between failure and CT characteristics, including phase, enrollment, funding source, intervention type, and age-eligibility criteria, was analyzed using descriptive statistics and multivariable regression models. RESULTS: A total of 692 matched trials were analyzed, including 346 trial failures and 346 completed control trials. The overall leading reasons for failure were strategic decisions (defined as nonscientific, sponsor-driven choices; 102 trials [29.5%]) and poor recruitment (90 trials [26.0%]). The reasons for failure varied by trial characteristics. Strategic decisions were the predominant reason for failure in phase 1 trials, industry-sponsored trials, and immunotherapy and targeted therapy trials. In contrast, poor recruitment was a more common reason in later-phase trials, non-industry-sponsored trials, and trials investigating chemotherapy, radiation, chemoradiation, combination treatments, and supportive care. Temporal analysis revealed a growing failure rate among CTs since 2000. Increased log-transformed actual enrollment safeguarded against trial failure, whereas industry funding was an independent risk factor. CONCLUSIONS AND RELEVANCE: In this study, HNSCC CTs were terminated early or withdrawn for a variety of reasons, most commonly due to strategic decisions or poor recruitment. Careful attention to trial characteristics associated with early failure is needed to overcome new barriers to drug development and adapt trial design to common reasons for failure.</description>
    </item>
  </channel>
</rss>
